Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. ACN
9. AZN
10. SPCX

Go back to Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress

Twist Bioscience Corporation (TWST) Tops Q2 EPS by 4c, Revenues Beat; FY19 Revenue Guidance Above Consensus

April 30, 2019 5:07 PM EDT

Twist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($0.93), $0.04 better than the analyst estimate of ($0.97). Revenue for the quarter came in at $13.56 million versus the consensus estimate of $12.02 million.

We continue to post strong topline growth as we extend our reach and diversify our revenue stream from our synbio customers, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. For NGS, we continue to expand our base of customers rapidly, adding several in production and a larger number in pilot. Importantly, we... More